Related references
Note: Only part of the references are listed.Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis
Ang Li et al.
THROMBOSIS RESEARCH (2019)
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
A. A. Khorana et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States
Ang Li et al.
THROMBOSIS RESEARCH (2019)
Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis
Nathan T. Connell et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis
Ang Li et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Marc Carrier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Gary E. Raskob et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature
Yvonne M. Ende-Verhaar et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer A population-based cohort study
Alexander T. Cohen et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol
Holger J. Schunemann et al.
BMJ OPEN (2016)
Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial
Susan R. Kahn et al.
LANCET (2014)
Prophylaxis against Venous Thromboembolism in Ambulatory Patients with Cancer
Jean M. Connors
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Updating Cost-Effectiveness - The Curious Resilience of the $50,000-per-QALY Threshold
Peter J. Neumann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer
Carlos Martinez et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
Estimating Quality of Life in Acute Venous Thrombosis
Kerstin Hogg et al.
JAMA INTERNAL MEDICINE (2013)
Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States
Alok A. Khorana et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2013)
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation
D. Papaioannou et al.
HEALTH TECHNOLOGY ASSESSMENT (2012)
Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Dorothy Romanus et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2012)
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Excess Costs Associated with Patients with Pulmonary Arterial Hypertension in a US Privately Insured Population
Noam Kirson et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2011)
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
Giancarlo Agnelli et al.
LANCET ONCOLOGY (2009)
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial
Desmond Curran et al.
QUALITY OF LIFE RESEARCH (2009)
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana et al.
BLOOD (2008)
Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome
Janice S. Kwon et al.
CANCER (2008)
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
A. A. Khorana et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Long-term cost of stroke subtypes among medicare beneficiaries
Won Chan Lee et al.
CEREBROVASCULAR DISEASES (2007)
Whither trial-based economic evaluation for health care decision making?
Mark J. Sculpher et al.
HEALTH ECONOMICS (2006)
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States
JA Caprini et al.
VALUE IN HEALTH (2003)
Prognosis of cancers associated with venous thromboembolism.
HT Sorensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
